Prophylaxis and treatment of hepatitis B in immunocompromised patients.
about
Current trends in management of hepatitis B virus reactivation in the biologic therapy eraHepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel diseaseTreatment of autoimmune hemolytic anemiasClinical impact of occult hepatitis B virus infection in immunosuppressed patientsCancer and liver cirrhosis: implications on prognosis and managementManagement of psoriasis patients with hepatitis B or hepatitis C virus infectionTreatment of rheumatic diseases and hepatitis B virus coinfectionChallenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Occult hepatitis B virus and hepatocellular carcinomaManagement of occult hepatitis B virus infection: an update for the clinician.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reportsManagement of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugsManagement of chronic hepatitis B in patients from special populations'Les liaisons dangereuses': Hepatitis C, Rituximab and B-cell non-Hodgkin's lymphomas.Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.Rituximab-based treatment, HCV replication, and hepatic flares.Occult HBV infection.Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patientsInterferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials.Use of infliximab in particular clinical settings: management based on current evidence.Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component.Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists.Treatment of special populations with chronic hepatitis B infection.Should cirrhosis change our attitude towards treating non-hepatic cancer?Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management.Patients with hematological malignancies and serological signs of prior resolved hepatitis B.Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature.Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.Hepatic RNA Interference: Delivery by Synthetic Vectors.Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia.Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues.The prognosis and management of inactive HBV carriers.Occult HBV infection in the oncohematological setting.Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders.Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia.
P2860
Q24634879-6956075C-E329-490C-9C7C-1DEAE66FDF96Q26827444-2A0AA5FB-AEA0-4944-B0AC-572BE518D357Q26866954-44DFA08C-F15B-4201-ABBE-4EB015DE8208Q27006996-EF137C1A-AE66-40A7-9F94-4E1B2B7AC9C4Q28068579-6F2FC428-5200-44A9-9EB7-AFB3F4A878FBQ28078157-13FE9CB9-E699-4550-9D75-FCDEE8AA1D42Q28084305-52E93E16-3AEC-4D4E-A0F7-C0FF8055BE36Q30244767-ACC7332B-A85E-4EB2-BEA0-592BC6BF16E6Q30391932-D77BDA12-6BDA-4C8C-B20A-ADC8F729CB7AQ33661018-67F98368-E2F1-48FB-9A57-167B2D09CBECQ34757408-0150A57B-E8B2-4C73-A98D-D44E13B0928DQ34854165-52F8F4FC-EA1A-409D-B9FF-179A1FF8FBD9Q35095916-93F19ECB-3C7D-4CD5-8F29-2F49C22FB6B5Q35610251-855E1EBC-380D-4C83-BDC9-CF5F3A06E257Q35664183-6615E140-7D9D-4BF6-B37C-86F9CD292696Q35948807-A0938C42-516C-49D6-8C6F-F1B716909E2CQ36121117-FCBDFDA1-F014-4DD2-8539-5C4BFC968A93Q36167378-7181EFDE-0B6D-4819-873E-7A4E0FA642C1Q36518847-5416E60B-71AE-45F1-8603-4CE8BF9BF6ADQ36757744-86052F72-7284-42BD-A611-E4EE7E602AF8Q37053900-71B9ACEB-D71E-4718-8A0B-3B26207A88AAQ37506064-B5C848C4-A943-4DEB-8D64-4DACC6BEF9D0Q37685724-F4CBA347-6752-4E1C-8AFD-6A9B1C37E942Q37714705-297A2295-E05F-4187-B081-61AF3557A248Q37886158-9E0A6FA8-9A53-478C-B77B-6010610BD494Q37958071-2977DF5B-ECA5-4DCD-90A6-57138B2D37FFQ37970447-D1A99EFF-8071-499B-8732-1311D41E8058Q37999022-D81427C6-4894-4923-ACB6-F2D0A57492D7Q38134026-BE25847B-429D-4D33-97CD-C92B7B510543Q38168296-D4CE6A97-ACC1-4079-B850-55D87B01CDE2Q38200096-A4D1DF1C-8573-4288-BAFA-513E60725951Q38253568-8955E596-9C93-49C5-AFF7-EB9832779C82Q38397403-C5A9E2D0-02A7-4ABA-8BDD-7159353B39D9Q38421916-34CD4BC3-957A-488C-8FD5-7A5004907EF3Q38539281-D0340EBC-572A-4E17-9940-A7A0FB2A9F31Q38685595-45B87905-35C0-44A2-ABFC-5941F569132BQ38807875-E495280F-2AF5-4BDB-9BD7-DB365F633975Q38810735-3B532700-AB79-491F-A179-04FC0A01D4ABQ38815080-829444A6-28E2-4B33-9094-CD7CF901FCFFQ40003713-F196EFB7-0F4C-41F7-850A-AFF588E5FC73
P2860
Prophylaxis and treatment of hepatitis B in immunocompromised patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Prophylaxis and treatment of hepatitis B in immunocompromised patients.
@ast
Prophylaxis and treatment of hepatitis B in immunocompromised patients.
@en
type
label
Prophylaxis and treatment of hepatitis B in immunocompromised patients.
@ast
Prophylaxis and treatment of hepatitis B in immunocompromised patients.
@en
prefLabel
Prophylaxis and treatment of hepatitis B in immunocompromised patients.
@ast
Prophylaxis and treatment of hepatitis B in immunocompromised patients.
@en
P2093
P50
P1476
Prophylaxis and treatment of hepatitis B in immunocompromised patients.
@en
P2093
G Raimondo
Italian Association for the Study of the Liver
M Brunetto
P Andreone
P304
P356
10.1016/J.DLD.2006.12.017
P577
2007-03-26T00:00:00Z